Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for livestock, poultry, and pets. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.
Research context
Pulike Biological Engineering, Inc appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Pulike Biological Engineering, Inc is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 28.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Pulike Biological Engineering, Inc's total revenue rose by 46.2% to $281M since the same quarter in the previous year.
Its net income has increased by 296.3% to $56M since the same quarter in the previous year.
Finally, its free cash flow grew by 81.3% to $82M since the same quarter in the previous year.
Based on the above factors, Pulike Biological Engineering, Inc gets an overall score of 5/5.